



ASX ANNOUNCEMENT

1 July 2025

Professor Miles Prince appointed as Non-Executive Director

Sydney, Australia, 1 July 2025: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to announce the appointment of Professor H. Miles Prince AM as a Non-Executive Director, effective 1 July 2025.

Professor Prince is an internationally recognised haematologist and Professor of Medicine at both Melbourne and Monash Universities. He holds the position of Professor and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and serves as a Haematologist at the Peter MacCallum Cancer Centre. His extensive experience encompasses clinical practice, groundbreaking research in cancer immunology, stem cell therapies, and leadership in clinical trials involving innovative treatments for blood cancers.

Professor Prince has been the Principal Investigator for over 200 clinical trials, notably leading the establishment of the Cell Therapy laboratories at the Peter MacCallum Cancer Centre and pioneering CAR-T therapy trials at both Peter MacCallum and Epworth Healthcare. His contributions to the field are also well recognised with more than 500 peer-reviewed manuscripts.

In addition to his clinical and research roles, Professor Prince is deeply involved in philanthropy and healthcare advocacy. He is a founding member of the Snowdome Foundation, dedicated to accelerating novel therapies for blood cancer patients in Australia. He also serves on the Australian Blood Cancer Taskforce, which recently developed Australia's first national Strategic Action Plan for Blood Cancer.

In recognition of his outstanding contributions to medicine, particularly blood cancer research, patient care, and philanthropic leadership, Professor Prince was appointed a Member of the Order of Australia (AM) in 2014.

Paul Hopper, Executive Chairman of Chimeric Therapeutics, commented: "We are very pleased to welcome Professor Prince to our Board. His unparalleled expertise in haematology, cancer immunology, and cell therapy will significantly bolster our strategic direction and clinical programs. Maintaining a long professional history with our CEO, his extensive clinical trial leadership and commitment to advancing innovative treatments align perfectly with our mission at Chimeric."

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company is focused on bringing the promise of cell therapy to life for more patients with cancer.



To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, Professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated.

CHM CLTX is a novel CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

**Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au